Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

H. Zuo; P. M. Ueland; Midttun; G. S. Tell; A. Fanidi; W. Zheng; X. Shu; Y. Xiang; J. Wu; R. Prentice; M. Pettinger; C. A. Thomson; G. G. Giles; A. Hodge; Q. Cai; W. J. Blot; M. Johansson; J. Hultdin; K. Grankvist; V. L. Stevens; M. L. McCullough; S. J. Weinstein; D. Albanes; R. G. Ziegler; N. D. Freedman; N. E. Caporaso; A. Langhammer; K. Hveem; M. Næss; J. E. Buring; I. Lee; J. M. Gaziano; G. Severi; X. Zhang; M. J. Stampfer; J. Han; A. Zeleniuch-Jacquotte; L. L. Marchand; J. Yuan; R. Wang; W. Koh; Y. Gao; U. Ericson; K. Visvanathan; M. R. Jones; C. Relton; P. Brennan; M. Johansson; A. Ulvik

doi:10.1093/annonc/mdz002

Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

H. Zuo, P. M. Ueland, Midttun, G. S. Tell, A. Fanidi, W. Zheng, X. Shu, Y. Xiang, J. Wu, R. Prentice, M. Pettinger, C. A. Thomson, G. G. Giles, A. Hodge, Q. Cai, W. J. Blot, M. Johansson, J. Hultdin, K. Grankvist, V. L. StevensM. L. McCullough, S. J. Weinstein, D. Albanes, R. G. Ziegler, N. D. Freedman, N. E. Caporaso, A. Langhammer, K. Hveem, M. Næss, J. E. Buring, I. Lee, J. M. Gaziano, G. Severi, X. Zhang, M. J. Stampfer, J. Han, A. Zeleniuch-Jacquotte, L. L. Marchand, J. Yuan, R. Wang, W. Koh, Y. Gao, U. Ericson, K. Visvanathan, M. R. Jones, C. Relton, P. Brennan, M. Johansson, A. Ulvik

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

Original language	English (US)
Pages (from-to)	478-485
Number of pages	8
Journal	Annals of Oncology
Volume	30
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdz002
State	Published - Mar 1 2019

Keywords

Lung Cancer Cohort Consortium
PAr
inflammation
lung cancer
nested case-control study
vitamin B6

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz002

Cite this

Zuo, H., Ueland, P. M., Midttun, Tell, G. S., Fanidi, A., Zheng, W., Shu, X., Xiang, Y., Wu, J., Prentice, R., Pettinger, M., Thomson, C. A., Giles, G. G., Hodge, A., Cai, Q., Blot, W. J., Johansson, M., Hultdin, J., Grankvist, K., ... Ulvik, A. (2019). Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3). Annals of Oncology, 30(3), 478-485. https://doi.org/10.1093/annonc/mdz002

Zuo, H, Ueland, PM, Midttun, Tell, GS, Fanidi, A, Zheng, W, Shu, X, Xiang, Y, Wu, J, Prentice, R, Pettinger, M, Thomson, CA, Giles, GG, Hodge, A, Cai, Q, Blot, WJ, Johansson, M, Hultdin, J, Grankvist, K, Stevens, VL, McCullough, ML, Weinstein, SJ, Albanes, D, Ziegler, RG, Freedman, ND, Caporaso, NE, Langhammer, A, Hveem, K, Næss, M, Buring, JE, Lee, I, Gaziano, JM, Severi, G, Zhang, X, Stampfer, MJ, Han, J, Zeleniuch-Jacquotte, A, Marchand, LL, Yuan, J, Wang, R, Koh, W, Gao, Y, Ericson, U, Visvanathan, K , Jones, MR, Relton, C, Brennan, P, Johansson, M & Ulvik, A 2019, 'Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)', Annals of Oncology, vol. 30, no. 3, pp. 478-485. https://doi.org/10.1093/annonc/mdz002

@article{25cc1a6b407d4474a1e2750537c72c96,

title = "Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)",

abstract = "Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.",

keywords = "Lung Cancer Cohort Consortium, PAr, inflammation, lung cancer, nested case-control study, vitamin B6",

author = "H. Zuo and Ueland, {P. M.} and Midttun and Tell, {G. S.} and A. Fanidi and W. Zheng and X. Shu and Y. Xiang and J. Wu and R. Prentice and M. Pettinger and Thomson, {C. A.} and Giles, {G. G.} and A. Hodge and Q. Cai and Blot, {W. J.} and M. Johansson and J. Hultdin and K. Grankvist and Stevens, {V. L.} and McCullough, {M. L.} and Weinstein, {S. J.} and D. Albanes and Ziegler, {R. G.} and Freedman, {N. D.} and Caporaso, {N. E.} and A. Langhammer and K. Hveem and M. N{\ae}ss and Buring, {J. E.} and I. Lee and Gaziano, {J. M.} and G. Severi and X. Zhang and Stampfer, {M. J.} and J. Han and A. Zeleniuch-Jacquotte and Marchand, {L. L.} and J. Yuan and R. Wang and W. Koh and Y. Gao and U. Ericson and K. Visvanathan and Jones, {M. R.} and C. Relton and P. Brennan and M. Johansson and A. Ulvik",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",

year = "2019",

month = mar,

day = "1",

doi = "10.1093/annonc/mdz002",

language = "English (US)",

volume = "30",

pages = "478--485",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Vitamin B6 catabolism and lung cancer risk

T2 - Results from the Lung Cancer Cohort Consortium (LC3)

AU - Zuo, H.

AU - Ueland, P. M.

AU - Midttun,

AU - Tell, G. S.

AU - Fanidi, A.

AU - Zheng, W.

AU - Shu, X.

AU - Xiang, Y.

AU - Wu, J.

AU - Prentice, R.

AU - Pettinger, M.

AU - Thomson, C. A.

AU - Giles, G. G.

AU - Hodge, A.

AU - Cai, Q.

AU - Blot, W. J.

AU - Johansson, M.

AU - Hultdin, J.

AU - Grankvist, K.

AU - Stevens, V. L.

AU - McCullough, M. L.

AU - Weinstein, S. J.

AU - Albanes, D.

AU - Ziegler, R. G.

AU - Freedman, N. D.

AU - Caporaso, N. E.

AU - Langhammer, A.

AU - Hveem, K.

AU - Næss, M.

AU - Buring, J. E.

AU - Lee, I.

AU - Gaziano, J. M.

AU - Severi, G.

AU - Zhang, X.

AU - Stampfer, M. J.

AU - Han, J.

AU - Zeleniuch-Jacquotte, A.

AU - Marchand, L. L.

AU - Yuan, J.

AU - Wang, R.

AU - Koh, W.

AU - Gao, Y.

AU - Ericson, U.

AU - Visvanathan, K.

AU - Jones, M. R.

AU - Relton, C.

AU - Brennan, P.

AU - Johansson, M.

AU - Ulvik, A.

N1 - Publisher Copyright: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

AB - Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

KW - Lung Cancer Cohort Consortium

KW - PAr

KW - inflammation

KW - lung cancer

KW - nested case-control study

KW - vitamin B6

UR - http://www.scopus.com/inward/record.url?scp=85064129265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064129265&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz002

DO - 10.1093/annonc/mdz002

M3 - Article

C2 - 30698666

AN - SCOPUS:85064129265

SN - 0923-7534

VL - 30

SP - 478

EP - 485

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this